Contrarian Corpus
short seller full deck follow up
2024-07-03 · 35 pages

Eurofins Scientific SE ERF

Eurofins' 800+ immaterial subsidiaries and 18 auditors enable sham sales and cash double-counting; new evidence, including a factoring denial contradicted by a former BU head, argues the financials cannot be trusted.

N 4 Narrative
V 2 Visual
C 2 Craft
Source URL unavailable

Thesis

In this Part II follow-up to its initial short report, Muddy Waters marshals new forensic evidence that Eurofins Scientific's balkanized structure — 1,300-1,500 legal entities, ~800-900 of them generating less than €5m of revenue, policed by at least 18 auditors with consolidation work run from India — is engineered to enable sham sales and inflated cash. The deck walks through the mechanism (invoice, related-party receivable, dividend netting, sham payable) and cites a €76.5m restatement at Eurofins Support Services Lux as evidence that large RP balances get netted routinely. It then contrasts Eurofins IR's flat denial of factoring with a former BU head's taped statement that factoring ran on both sides, and a senior tax executive's LinkedIn bio. Revenue and compensation per employee sit ~70% above Bureau Veritas, Intertek and SGS peers, and the 'no factoring' disclosure quietly vanished after 2020.

SCQA

Situation

Eurofins Scientific is a €9bn lab-testing group operating through roughly 1,300-1,500 legal entities across Europe, the US and beyond, with consolidation handled out of India and at least 18 different audit firms signing off.

Complication

That balkanized structure produces ~325,000 related-party receivables and payables per year and ~800-900 sub-€5m entities, giving management unaudited dials to fabricate revenue and classify related-party balances as Cash & Equivalents.

Resolution

Investors should stop taking Eurofins' financials at face value; management's denials on factoring, audit coverage and cash classification are misleading, directly contradicted by former insiders, subsidiary filings and Bureau Veritas precedent.

Reward

No explicit price target is set; Muddy Waters discloses it is short Eurofins and expects significant gains if equity or debt prices decline once the market re-rates the quality of reported revenue and cash.

The three reasons

  1. 1

    Eurofins has ~800-900 immaterial entities and 18 auditors, creating chaos that can hide sham sales

  2. 2

    Management's on-record denial of factoring is contradicted by a former BU head and a senior insider's LinkedIn

  3. 3

    Subsidiary restatements (e.g. ESS Lux €76.5m, Genomics UK -99% cash) show routine netting and unreliable reporting

Primary demands

  • Do not take Eurofins' financials at face value
  • Treat management's denials (factoring, audit coverage, cash classification) as unreliable
  • Recognize that the balkanized entity and auditor structure enables sham revenue and cash inflation

KPIs cited

Number of auditors
At least 18 auditors across the Eurofins network, 13 in Europe alone
Immaterial entities count
~800-900 entities with <€5m revenue generating ~€1.5-1.7bn of 2022 revenue
Related-party journal entries
~325,000 RP pooling receivables and ~325,000 RP pooling payables per year
ESS Lux restatement
2017 RP Payables restated down €76.5m, netted against €75.0m of RP Receivables
Revenue per employee
Eurofins ~€115k in 2023 vs peer average ~€75k (Bureau Veritas, Intertek, SGS)
Personnel cost per employee
Eurofins ~€54k in 2023 vs peer average ~€36k
Deloitte audit coverage
71% of external sales covered by Deloitte's consolidated audit; 29% not covered
Genomics UK anomaly
Zero employees, £3.4m first-year revenue, -99% downward cash restatement in 2023

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • Bureau Veritas (peer that classifies related-party pooling as financial assets, not cash equivalents)
  • Intertek and SGS (peer benchmarks on revenue and cost per employee)

Notable slides (6)

Notes

Part II follow-up to Muddy Waters' initial Eurofins short report, focused on netting/eliminations mechanics rather than a fresh thesis. Dense with French/Spanish statutory-filing screenshots. Author_name set to null because the deck is signed only by the firm. No explicit target price — standard Muddy Waters posture of short disclosure in disclaimer plus forensic argument. Dr. Martin referenced as villain but not the primary rhetorical target here; IR and the company's public rebuttal are.